Expression of SHP2 and related markers in non-small cell lung cancer: A tissue microarray study of 80 cases

Applied Immunohistochemistry and Molecular Morphology

Volumn 21, Issue 5, 2013, Pages 386-394

  Tang, Chunlan ^a   Luo, Dan ^a   Yang, Heping ^a   Wang, Qingliang ^a   Zhang, Rong ^a   Liu, Guoxiang ^a   Zhou, Xiangdong ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

SHP2 non small cell lung cancer; tissue microarray

Indexed keywords

GELATINASE A; GELATINASE B; PROTEIN TYROSINE PHOSPHATASE SHP 2; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ARTICLE; CANCER SURVIVAL; CAPILLARY DENSITY; CONTROLLED STUDY; DISEASE MARKER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; TISSUE MICROARRAY;

ADENOCARCINOMA; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICROVESSELS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11; SENSITIVITY AND SPECIFICITY; TISSUE ARRAY ANALYSIS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84885034861     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e31827da3f9     Document Type: Article

References (26)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
2. D'Amico TA. Angiogenesis in non-small cell lung cancer. Semin Thorac Cardiovasc Surg. 2004;16:13-18.
3. Müller-Tidow C, Diederichs S, Thomas M, et al. Genome-wide screening for Prognosis- redicting genes in early-stage non-smallcell lung cancer. Lung Cancer. 2004;45(suppl 12):S145-S150.
4. Arias-Romero LE, Saha S, Villamar-Cruz O, et al. Activation of Src by Protein tyrosine phos hatase 1B is required for ErbB2transformation of human breast e ithelial cells. Cancer Res. 2009;69: 4582-4588.
5. Burgoyne AM, Phillis-Mason J, Burden-Gulley SM, et al. Proteolytic cleavage of Protein tyrosine phos hatase mu regulates glioblastoma cell migration. Cancer Res. 2009;69:6960-6968.
6. Caron D, Savard E, Doillon CJ, et al. Protein tyrosine phos hatase inhibition induces anti-tumor activity: evidence of Cdk2/ 27 ki 1 and Cdk2/SH -1 com lex formation in human ovarian cancer cells. Cancer Lett. 2008;262:265-275.
7. Chan G, Kalaitzidis D, Neel BG. The tyrosine phos hatase Sh 2 (PTPN11) in cancer. Cancer Metastasis Rev. 2008;27:179-192.
8. Wang S, Yu WM, Zhang W, et al. Noonan syndrome/leukemiaassociated gain-of-function mutations in SH -2 phos hatase (PTPN11) enhance cell migration and angiogenesis. J Biol Chem. 2009;284:913-920.
9. Wu D, Pang Y, Ke Y, et al. A conserved mechanism for control of human and mouse embryonic stem cell pluripotency and differentiation by shp 2 tyrosine phos hatase. LoS One. 2009;4:e4914.
10. Yang X, Dutta U, Shaw LM. SH 2 mediates the localized activation of Fyn downstream of the al ha6beta4 integrin to promote carcinoma invasion. Mol Cell Biol. 2010;30:5306-5317.
11. Sounni NE, Rozanov DV, Remacle AG, et al. Tim -2 binding with cellular MT1-MMP stimulates invasion-promoting MEK/ERK signaling in cancer cells. Int J Cancer. 2010;126:1067-1078.
12. Waleh NS, Murphy BJ, Zaveri NT. Increase in tissue inhibitor of metallo roteinase-2 (TIM -2) levels and inhibition of MM -2 activity in a metastatic breast cancer cell line by an anti-invasive small molecule SR13179. Cancer Lett. 2010;289:111-118.
13. Liu KW, Feng H, Bachoo R, et al. SH -2/ T N11 mediates gliomagenesis driven by PDGFRA and INK4A/ARF aberrations in mice and humans. J Clin Invest. 2011;121:905-917.
14. Ellis LM, Hicklin DJ. VEGF-targeted thera y: mechanisms of antitumor activity. Nat Rev Cancer. 2008;8:579-591.
15. Okumura T, Asamura H, Suzuki K, et al. Intra ulmonary metastasis of non-small cell lung cancer: a prognostic assessment. J Thorac Cardiovasc Surg. 2001;122:24-28.
16. Fu XL, Zhu XZ, Shi DR, et al. Study of prognostic predictors for non-small cell lung cancer. Lung Cancer. 1999;23:143-152.
17. Hung JJ, Jeng WJ, Hsu WH, et al. prognostic factors of postrecurrence survival in com letely resected stage I non-small cell lung cancer with distant metastasis. Thorax. 2010;65:241-245.
18. Bentires-Alj M, Paez JG, David FS, et al. Activating mutations of the Noonan syndrome-associated SH 2/ T N11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res. 2004;64:8816-8820.
19. Thomas P, Khokha R, Shepherd FA, et al. Differential ex ression of matrix metallo roteinases and their inhibitors in non-small cell lung cancer. J Pathol. 2000;190:150-156.
20. Zheng S, Chang Y, Hodges KB, et al. Expression of KISS1 and MM -9 in non-small cell lung cancer and their relations to metastasis and survival. Anticancer Res. 2010;30:713-718.
21. Lin TS, Chiou SH, Wang LS, et al. Ex ression s ectra of matrix metallo roteinases in metastatic non-small cell lung cancer. Oncol Rep. 2004;12:717-723.
22. Foda HD, Zucker S. Matrix metallo roteinases in cancer invasion, metastasis and angiogenesis. Drug Discov Today. 2001;6: 478-482.
23. Ylisirnio S, Hoyhtya M, Turpeenniemi-Hujanen T. Serum matrix metallo roteinases -2, -9 and tissue inhibitors of metallo roteinases -1, -2 in lung cancer-TIM -1 as a Prognostic marker. Anticancer Res. 2000;20:1311-1316.
24. Shijubo N, Uede T, Kon S, et al. Vascular endothelial growth factor and osteo ontin in stage I lung adenocarcinoma. Am J Respir Crit Care Med. 1999;160:1269-1273.
25. Decaussin M, Sartelet H, Robert C, et al. Ex ression of vascular endothelial growth factor (VEGF) and its two rece tors (VEGF-R1- Flt1 and VEGF-R2-Flk1/KDR) in non-small cell lung carcinomas (NSCLCs): correlation with angiogenesis and survival. J Pathol. 1999;188:369-377.
26. Mitola S, Brenchio B, Piccinini M, et al. Type I collagen limits VEGFR-2 signaling by a SH 2 Protein-tyrosine phos hatasede endent mechanism 1. Circ Res. 2006;98:45-54.